Business
Positron Corporation Secures $8 Million in Capital to Accelerate Growth and Market Expansion
Niagara Falls, NY, March 31, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT imaging systems and clinical support services, is pleased to announce it has secured $8 million in capital to accelerate its expansion in the PET-CT market and further strengthen its position as a premier provider of advanced imaging technology and services for nuclear cardiology an
About this update from Positron Corp.
[{"type":"image","alt":"Positron Corp.","displaySize":"","headline":null,"caption":"Positron Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":202,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/ebd791e43d08d174777a55da181a7ab0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xunCpPZoEliw3qdBzv.R.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ebd791e43d08d174777a55da181a7ab0","width":202,"height":90}},"lazy":false},{"type":"text","content":"Niagara Falls, NY, March 31, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT imaging systems and clinical support services, is pleased to announce it has secured $8 million in capital to accelerate its expansion in the PET-CT market and further strengthen its position as a premier provider of advanced imaging technology and services for nuclear cardiology and oncology. The investment was exclusively equity based, offering 8 million shares of its common stock to two strategic investors.","length":630,"tagName":"p"},{"type":"text","content":"This investment will enable Positron to advance its strategic initiatives, including sales and marketing efforts and sales personnel, enhancing its current and future product offerings and further solidifying its partnerships within the nuclear medical imaging industry. The Company anticipates this capital to drive Positron’s advancement of the PET modality, strengthen its presence in North America and support future expansion to European markets. Additionally, it will be a significant foundation for the Company to resume SEC filings and move toward uplisting on a senior stock exchange. ","length":600,"tagName":"p"},{"type":"text","content":"Additionally, this capital raise aligns with Positron’s long-term vision of collaborating with current and future strategic alliances, enhancing its technology portfolio, and expanding its global footprint. The Company remains committed to driving innovation in molecular imaging and ensuring that more healthcare providers have access to the most advanced diagnostic tools available.","length":384,"tagName":"p"},{"type":"text","content":"Adel Abdullah, President of Positron, stated, "Positron is now we...